研究单位：[1]Peking University Third Hospital[2]The Second Affiliated Hospital of Dalian Medical University[3]Peking University First Hospital[4]Beijing Hospital[5]Beijing Tsinghua Changgeng Hospital[6]China-Japan Friendship Hospital[7]Chinese PLA General Hospital[8]First Affiliated Hospital of Harbin Medical University[9]Baotou Cancer Hospital[10]Beijing Shijitan Hospital,Capital Medical University[11]Shanxi Province Cancer Hospital[12]Beijing Naval General Hospital[13]First Hospital of China Medical University[14]Jilin Provincial Tumor Hospital[15]Shengjing Hospital[16]307 Hospital of PLA[17]Peking Union Medical College Hospital[18]Harbin Medical University[19]Beijing Tongren Hospital
The purpose of the study is to better and systematically collect clinical data on the treatment of ibrutinib combined with R-CHOP/DHAP regimen for more scientific and accurate evaluation, our center has carried out the R-CHOP/R-DHAP alternative regimen combined with ibrutinib at age ≤ An observational clinical study on the safety and effectiveness of 65-year-old mantle cell lymphoma. Through this study, young mantle cell lymphomas in the Chinese population can be collected. Ibrutinib combined with R-CHOP/R-DHAP is used in the initial treatment. 2 and 6 cycles of ORR were used to evaluate survival indicators, and collect adverse reactions during treatment and recurrence rate after treatment.
